Drug Profile
Research programme: adrenergic beta 3 receptor agonists - Eli Lilly and Company
Latest Information Update: 03 Apr 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Benzimidazoles; Obesity therapies
- Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists; Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity; Syndrome X; Type 2 diabetes mellitus
Most Recent Events
- 31 Mar 2009 No development reported - Preclinical for Obesity in USA (unspecified route)
- 31 Mar 2009 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 16 Apr 2007 Preclinical trials in Obesity in USA (unspecified route)